research Study on the mechanism that SNPs related to sex hormone metabolism regulate the imbalance of sex hormones and lead to BPHin rats
Combining anastrozole with finasteride may better treat hormone imbalance in BPH.
Search
for
Sort by
Research
990-1000 / 1000+ results research 76976 Association of Depression with Finasteride Stratified by Dosage and Diagnosis: A Retrospective Cohort Study Using the TriNetX Database
Finasteride may lower depression risk in younger men with hair loss but increase it in older men with prostate issues.
research The urologic impact of long-term finasteride 1-mg use for androgenic alopecia: a matched-cohort database analysis
Long-term finasteride use may lead to earlier use of ED medication and lower prostate cancer diagnosis rates.
research Isolation and Structural Characterization of Finasteride Degradation Products by Preparative HPLC, HRMS, and NMR
Finasteride breaks down into new compounds under acidic conditions.
research Finasteride. dutasteride risk of suicide and sexual dysfunction
Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.
research Persistent Sexual and Psychological Symptoms After Finasteride Discontinuation: A Cross-Sectional Observational Study
Stopping finasteride can lead to lasting sexual and psychological issues.
research METHOD DEVELOPMENT AND VALIDATION OF UV-SPECTROPHOTOMETRIC ESTIMATION OF FINASTERIDE IN BULK AND PHARMACEUTICAL DOSAGE FORM
A reliable, cost-effective method was developed for accurately measuring finasteride in medicines.
research FINASTERIDE IN MODERN MEDICINE: THERAPEUTIC APPLICATIONS AND SYSTEMIC HEALTH IMPLICATIONS
Finasteride is effective for hair loss and prostate issues but may cause lasting side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.